Current as of 06/06/2023

Chris is a non-executive director of Clarity Pharmaceuticals Limited (ASX:CU6), HealthCo (Healthcare and Wellness REIT ASX:HCW), HMC Capital Partners Fund I, AtmoBiosciences Limited, Nutromics Pty Ltd and O’Connell Street Associates Pty Ltd and sits on the board of the Centenary Institute of Medical Research and the Cochlear Foundation.

Chris was Chair of the Board (2019 – 2023) of The Engineering and Design Institute - London (TEDI-London), a joint venture between UNSW, Arizona State University and King’s College London focused on transforming engineering education in the UK.

Chris was CEO/President of Cochlear Ltd (ASX:COH) from 2004 to 2015, an executive director of ResMed Inc (ASX:RMD, NYSE:RMD) from 1992 to 2003 and non-executive director of ResMed Inc from 2004 to 2017. He is a Fellow of the Academy of Technological Sciences and Engineering, The Australian Institute of Company Directors and an Honorary Fellow of The Institution of Engineers Australia. Chris holds a BE (Honours) in Chemical Engineering (UNSW), an MBA (Macq) and a PhD (UNSW). He was awarded Hon D Sc degrees from Macquarie University and UNSW, and an AO in 2017.

Dr Roberts has combined engineering and management skills to take innovative Australian products in dialysis, orthopedics, cardiology, and respiratory medicine to world markets.

He was instrumental in having Australian-developed implantable bone growth stimulators for spinal fusion accepted internationally, He has changed the direction of one company from an importer to a local manufacturer of innovative blood treatment products, and was instrumental in bringing novel treatments of intractable cancers to late stage clinical trials.